Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk
Open accessThe DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
AIMS: High-density lipoproteins (HDLs) are considered as anti-atherogenic. Recent experimental findings suggest that their biological properties can be modified in certain clinical conditions by accumulation of serum amyloid A (SAA). The effect of SAA on the association between HDL-cholesterol (HDL-C) and cardiovascular outcome remains unknown. METHODS AND RESULTS: We examined the association of SAA and HDL-C with mortality in the Ludwigshafen Risk and Cardiovascular Health (LURIC) study, which included 3310 patients undergoing coronary angiography. To validate our findings, we analysed 1255 participants of the German Diabetes and Dialysis study (4D) and 4027 participants of the Cooperative Health Research in the Region of Augsburg (KORA) S4 study. In LURIC, SAA concentrations predicted all-cause and cardiovascular mortality. In patients with low SAA, higher HDL-C was associated with lower all-cause and cardiovascular mortality. In contrast, in patients with high SAA, higher HDL-C was associated with increased all-cause and cardiovascular mortality, indicating that SAA indeed modifies the beneficial properties of HDL. We complemented these clinical observations by in vitro experiments, in which SAA impaired vascular functions of HDL. We further derived a formula for the simple calculation of the amount of biologically 'effective' HDL-C based on measured HDL-C and SAA from the LURIC study. In 4D and KORA S4 studies, we found that measured HDL-C was not associated with clinical outcomes, whereas calculated 'effective' HDL-C significantly predicted better outcome. CONCLUSION: The acute-phase protein SAA modifies the biological effects of HDL-C in several clinical conditions. The concomitant measurement of SAA is a simple, useful, and clinically applicable surrogate for the vascular functionality of HDL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Ridker, P. M., Hennekens, C. H., Buring, J. E., & Rifai, N. (2000) · New England Journal of Medicine · doi:10.1056/nejm200003233421202 · Cited by 5,850 · cited 5×
“In summary, these findings indicate that the concept of calculating biologically effective HDL-C′ may be applicable to patients with manifest, prevalent, and without CVD. Limitations of our study are that the LURIC, 4D, and KORA S4 studies primarily included patients of Caucasian ancestry, which limits the extension o…”
BackgroundInfluentialEffects of torcetrapib in patients at high risk for coronary events
Barter, P. J., Caulfield, M., Eriksson, M., Grundy, S. M., Kastelein, J. J. P., Komajda, M., Lopez-Sendon, J., Mosca, L., Tardif, J.-C., Waters, D. D., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706628 · Cited by 3,139 · cited 1×
“Large trials using the CETP inhibitors torcetrapib and dalcetrapib did not show a reduction of cardiovascular outcomes.(31,32) In these study programmes, a substantial proportion of Figure 3 HRs of tertiles of measured and calculated biologically effective HDL-C for the primary composite endpoint as well as all-cause…”
MethodAtorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis
Wanner, C., Krane, V., März, W., Olschewski, M., Mann, J. F. E., Ruf, G., & Ritz, E. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043545 · Cited by 2,614
Self-citationEffects of dalcetrapib in patients with a recent acute coronary syndrome
Schwartz, G. G., Olsson, A. G., Abt, M., Ballantyne, C. M., Barter, P. J., Brumm, J., Chaitman, B. R., Holme, I. M., Kallend, D., Leiter, L. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1206797 · Cited by 2,022
Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses
Danesh, J. (2000) · BMJ · doi:10.1136/bmj.321.7255.199 · Cited by 1,692 · cited 4×
“In summary, these findings indicate that the concept of calculating biologically effective HDL-C′ may be applicable to patients with manifest, prevalent, and without CVD. Limitations of our study are that the LURIC, 4D, and KORA S4 studies primarily included patients of Caucasian ancestry, which limits the extension o…”
BackgroundInfluentialRidker, P. M., Rifai, N., Pfeffer, M., Sacks, F., Lepage, S., & Braunwald, E. (2000) · Circulation · doi:10.1161/01.cir.101.18.2149 · Cited by 934
Sorrentino, S. A., Besler, C., Rohrer, L., Meyer, M., Heinrich, K., Bahlmann, F. H., Mueller, M., Horváth, T., Doerries, C., Heinemann, M., et al. (2010) · Circulation · doi:10.1161/circulationaha.108.836346 · Cited by 402 · cited 3×
“In vivo administration of reconstituted HDL to hypercholesterolaemic men has been demonstrated to improve endothelial function.6 Accordingly, observational trials have linked high concentrations of HDL-cholesterol (HDL-C) to improve the cardiovascular outcome.7 We and others have previously shown that HDLs may lose th…”
BackgroundSerum Amyloid A in Uremic HDL Promotes Inflammation
Weichhart, T., Kopecky, C., Kubicek, M., Haidinger, M., Döller, D., Katholnig, K., Suarna, C., Eller, P., Tölle, M., Gerner, C., et al. (2012) · Journal of the American Society of Nephrology · doi:10.1681/asn.2011070668 · Cited by 201
Self-citationLewis, K. E., Kirk, E. A., McDonald, T. O., Wang, S., Wight, T. N., O’Brien, K. D., & Chait, A. (2004) · Circulation · doi:10.1161/01.cir.0000136819.93989.e1 · Cited by 163 · cited 1×
“Moreover, SAA-enriched HDL may be associated with the development of atherosclerotic lesions in mice.(30) In experimental studies, we observed that SAA-supplemented HDL reduced endothelial NO production and concomitantly increased endothelial production of ROS.”
BackgroundHigh-density lipoprotein cholesterol, coronary artery disease, and cardiovascular mortality
Silbernagel, G., Schottker, B., Appelbaum, S., Scharnagl, H., Kleber, M. E., Grammer, T. B., Ritsch, A., Mons, U., Holleczek, B., Goliasch, G., et al. (2013) · European Heart Journal · doi:10.1093/eurheartj/eht343 · Cited by 123
Self-citation
Cited by
Soppert, J., Lehrke, M., Marx, N., Jankowski, J., & Noels, H. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.019 · Cited by 407
High-density lipoprotein revisited: biological functions and clinical relevance
von Eckardstein, A., Nordestgaard, B. G., Remaley, A. T., & Catapano, A. L. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehac605 · Cited by 401
HDL in the 21st Century: A Multifunctional Roadmap for Future HDL Research
Rohatgi, A., Westerterp, M., von Eckardstein, A., Remaley, A., & Rye, K.-A. (2021) · Circulation · doi:10.1161/circulationaha.120.044221 · Cited by 333
The heart and vascular system in dialysis
Wanner, C., Amann, K., & Shoji, T. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30508-6 · Cited by 303
Self-citationApolipoprotein C3 induces inflammation and organ damage by alternative inflammasome activation
Zewinger, S., Reiser, J., Jankowski, V., Alansary, D., Hahm, E., Triem, S., Klug, M., Schunk, S. J., Schmit, D., Kramann, R., et al. (2020) · Nature Immunology · doi:10.1038/s41590-019-0548-1 · Cited by 280
Self-citation
Metadata
- Authors
- Zewinger, S., Drechsler, C., Kleber, M. E., Dressel, A., Riffel, J., Triem, S., Lehmann, M., Kopecky, C., Säemann, M. D., Lepper, P. M., Silbernagel, G., Scharnagl, H., Ritsch, A., Thorand, B., de las Heras Gala, T., Wagenpfeil, S., Koenig, W., Peters, A., Laufs, U., Wanner, C., Fliser, D., Speer, T., & März, W.
- Venue
- European Heart Journal
- Publisher
- Oxford University Press (OUP)
- Published
- 2015-08-06
- Volume
- 36
- Issue
- 43
- Pages
- ehv352
- ISSN
- 0195-668X (ISSN-L)
- 1522-9645
- OpenAlex
- W2238837865
- Cited by
- 150
- References
- 11
- FWCI
- 12.73
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. https://app.cochat.ai/papers/10.1093/eurheartj/ehv352
- The paper
- Zewinger, S., Drechsler, C., Kleber, M. E., Dressel, A., Riffel, J., Triem, S., Lehmann, M., Kopecky, C., Säemann, M. D., Lepper, P. M., Silbernagel, G., Scharnagl, H., Ritsch, A., Thorand, B., de las Heras Gala, T., Wagenpfeil, S., Koenig, W., Peters, A., Laufs, U., . . . März, W. (2015). Serum amyloid A: high-density lipoproteins interaction and cardiovascular risk. European Heart Journal. https://doi.org/10.1093/eurheartj/ehv352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.